KRAS P.G12C

9 registered clinical trials studyying KRAS P.G12C — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tum NCT06008288	Allist Pharmaceuticals, Inc.	Phase 2
Active Not Recruiting	Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status NCT05673187	ETOP IBCSG Partners Foundation	Phase 2
Recruiting	Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C NCT05631249	Gustave Roussy, Cancer Campus, Grand Paris	Phase 2
Withdrawn	Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer NCT05251038	Devalingam Mahalingam	Phase 1 / Phase 2
Active Not Recruiting	Studying Pathways of Resistance in KRAS-driven Cancers NCT05272423	Addario Lung Cancer Medical Institute	—
Recruiting	A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12 NCT05410145	D3 Bio (Wuxi) Co., Ltd	Phase 1 / Phase 2
Recruiting	Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutat NCT05288205	Allist Pharmaceuticals, Inc.	Phase 1 / Phase 2
Recruiting	Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radioth NCT05398094	Fundación GECP	Phase 2
Unknown	RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC NCT05273047	Intergroupe Francophone de Cancerologie Thoracique	—